Gallwitz, B
It also isn't appropriate for everyone
Estimates suggest roughly 1015% of U.S
There is also the broader context of platform ecosystems, where integration, fairness audits, and promotions influence perception
By this point, most users have developed a rough sense of whether their symptoms are manageable or problematic
Here is a summary of the data for Alabama: Medicaid spending on GLP-1s (past 12 months): $43,100,970 Medicaid spending on GLP-1s (YoY change): +107% Medicaid spending on GLP-1s per enrollee (past 12 months): $55 Total Medicaid enrollment: 787,325 Wegovy coverage (obesity-indicated): Yes Zepbound coverage (obesity-indicated): No Saxenda coverage (obesity-indicated): No Ozempic coverage (Type 2 diabetes-indicated): Yes Mounjaro coverage (Type 2 diabetes-indicated): Yes Rybelsus coverage (Type 2 diabetes-indicated): Yes For reference, here are the statistics for the entire United States: Medicaid spending on GLP-1s (past 12 months): $3,452,602,033 Medicaid spending on GLP-1s (YoY change): +142% Medicaid spending on GLP-1s per enrollee (past 12 months): $48 Total Medicaid enrollment: 72,429,055 Wegovy coverage (obesity-indicated): 34 states Zepbound coverage (obesity-indicated): 16 states Saxenda coverage (obesity-indicated): 19 states Ozempic coverage (Type 2 diabetes-indicated): 51 states* Mounjaro coverage (Type 2 diabetes-indicated): 46 states* Rybelsus coverage (Type 2 diabetes-indicated): 46 states *Including District of Columbia For more information, a detailed methodology, and complete results, see Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending
